Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
The data highlights its RSV vaccine cuts hospitalizations in older adults
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
Subscribe To Our Newsletter & Stay Updated
